Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
TECX 
Tectonic Therapeutic, Inc. (TECX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: TECX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $79.75
1 Year Target Price $79.75
| 5 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 84.08% | Avg. Invested days 48 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 341.50M USD | Price to earnings Ratio 4.41 | 1Y Target Price 79.75 |
Price to earnings Ratio 4.41 | 1Y Target Price 79.75 | ||
Volume (30-day avg) 6 | Beta - | 52 Weeks Range 13.70 - 61.07 | Updated Date 11/3/2025 |
52 Weeks Range 13.70 - 61.07 | Updated Date 11/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 4.14 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -18.97% | Return on Equity (TTM) -29.32% |
Valuation
Trailing PE 4.41 | Forward PE - | Enterprise Value -78048 | Price to Sales(TTM) - |
Enterprise Value -78048 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 18712128 | Shares Floating 9741908 |
Shares Outstanding 18712128 | Shares Floating 9741908 | ||
Percent Insiders 38.39 | Percent Institutions 65.08 |
Upturn AI SWOT
Tectonic Therapeutic, Inc.
Company Overview
History and Background
Tectonic Therapeutic, Inc. is a biotechnology company focused on discovering and developing novel G protein-coupled receptor (GPCR)-targeted therapeutics. Founded in 2017, Tectonic has developed a platform to address challenging GPCR targets for a range of diseases. The company is relatively young and in the early stages of clinical development.
Core Business Areas
- GPCR-targeted therapeutics: Discovery and development of novel therapeutics targeting G protein-coupled receptors (GPCRs). GPCRs are important drug targets, but many remain underexplored due to technical challenges.
- Structural biology platform: Leveraging structural biology and computational methods to design therapeutics that selectively modulate GPCR function.
Leadership and Structure
Tectonic's leadership team comprises experienced biotechnology executives and scientists with expertise in GPCR biology and drug development. The company operates with a structure focused on research and development.
Top Products and Market Share
Key Offerings
- TT-101: TT-101 is Tectonic's lead program, targeting a specific GPCR for autoimmune diseases. The program is in preclinical or early clinical stages, therefore specific market share, user data or revenue figures are currently unavailable. Competitors in this space are companies targeting similar GPCRs or developing therapies for autoimmune diseases. Competitors are large pharma companies like AbbVie, Bristol Myers Squibb, Roche, etc. also smaller biotechs.
- TT-202: TT-202 is Tectonic's second program, also targeting a specific GPCR. Specific market share, user data or revenue figures are currently unavailable. Competitors in this space are companies targeting similar GPCRs or developing therapies. Competitors are large pharma companies like AbbVie, Bristol Myers Squibb, Roche, etc. also smaller biotechs.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive, with companies vying to develop innovative therapies for a wide range of diseases. GPCRs represent a significant class of drug targets, with a substantial market opportunity.
Positioning
Tectonic Therapeutic, Inc. is positioned as a company pioneering a novel approach to GPCR-targeted drug discovery. Its structural biology platform differentiates it from traditional drug development approaches. Early stage biotech company. Competitive advantage lies in the targetting of the GPCRs.
Total Addressable Market (TAM)
The TAM for GPCR-targeted therapeutics is substantial, estimated to be in the billions of dollars annually. Tectonic's positioning allows it to capture a share of this market by addressing previously undruggable GPCRs. TAM could exceed $100 billion across all GPCR targets.
Upturn SWOT Analysis
Strengths
- Proprietary GPCR-targeted drug discovery platform
- Experienced leadership team
- Focus on challenging and underexplored GPCR targets
- Strong intellectual property position
Weaknesses
- Early stage of development
- High cash burn rate
- Reliance on external funding
- Limited clinical data
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Advancement of pipeline candidates into clinical trials
- Validation of platform through successful drug approvals
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Changes in the regulatory environment
- Difficulties in raising capital
Competitors and Market Share
Key Competitors
- ABBV
- BMY
- MRK
- LLY
Competitive Landscape
Tectonic faces competition from established pharmaceutical companies with greater resources. Its advantage lies in its novel platform for GPCR-targeted drug discovery.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by preclinical development and platform validation.
Future Projections: Future growth is dependent on the success of clinical trials and potential partnerships.
Recent Initiatives: Recent initiatives likely include advancing lead programs into clinical development and securing financing.
Summary
Tectonic Therapeutic is an early-stage biotech company focused on GPCR-targeted therapeutics with a novel drug discovery platform. The company has a strong scientific team and a differentiated approach, but faces risks associated with clinical development and funding. Success depends on advancing its pipeline candidates and securing partnerships. It is strategically positioned within the GPCR-targeted therapeutics market. It's a high-risk, high-reward play, based on innovative approach.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- Press releases
- Analyst reports (where available)
- Publicly available information on competitors
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. The data is based on publicly available information and may not be comprehensive or accurate. Investment decisions should be based on independent research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tectonic Therapeutic, Inc.
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2018-06-21 | President, CEO, Secretary & Director Dr. Alise S. Reicin M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 51 | Website https://tectonictx.com |
Full time employees 51 | Website https://tectonictx.com | ||
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.